Current Issues and Challenges in the Use of Aerosolized Surfactant for Respiratory Distress Syndrome in the Newborns
BACKGROUND: Surfactant replacement therapy is a recognized treatment for respiratory distress syndrome (RDS) in the newborns. Over the past 30 years, human and animal trials have been performed regarding administration of aerosolized surfactant to the injured lung, however the result has been unsati...
Main Author: | Dion Darius Samsudin |
---|---|
Format: | Article |
Language: | English |
Published: |
Secretariat of The Indonesian Biomedical Journal
2013-08-01
|
Series: | Indonesian Biomedical Journal |
Online Access: | http://inabj.org/index.php/ibj/article/view/57 |
Similar Items
-
Aerosolized Surfactant for Preterm Infants with Respiratory Distress Syndrome
by: Mandy Brasher, et al.
Published: (2021-06-01) -
Comparison of the Efficacy of Three Natural Surfactants in Preterm Turkish Newborns with Respiratory Distress Syndrome
by: Fatma Hilal Yılmaz, et al.
Published: (2021-06-01) -
Aerosol Delivery of Lung Surfactant and Nasal CPAP in the Treatment of Neonatal Respiratory Distress Syndrome
by: Frans J. Walther, et al.
Published: (2022-06-01) -
Comparison of surfactant protein B polymorphisms of healthy term newborns with preterm newborns having respiratory distress syndrome
by: P.P.R. Lyra, et al.
Published: (2007-06-01) -
Outcome of Very Premature Newborn Receiving an Early Second Dose of Surfactant for Persistent Respiratory Distress Syndrome
by: Eva Greiner, et al.
Published: (2021-04-01)